A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
Study sponsor: Ionis Pharmaceuticals, Inc. · IONS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-12-17Actual
Enrollment · participants446Actual
Source updated2025-10-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.